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New treatments for obesity and associated metabolic disease are increasingly warranted
with the growth of the obesity pandemic. Brown adipose tissue (BAT) may represent a
promising therapeutic target to treat obesity, as this tissue has been shown to regulate
energy expenditure through non-shivering thermogenesis. Three different strategies
could be employed for therapeutic targeting of human thermogenic adipocytes:
increasing BAT mass through stimulation of BAT progenitors, increasing BAT function
through regulatory pathways, and increasing WAT browning through promotion of
beige adipocyte formation. However, these strategies require deeper understanding
of human brown and beige adipocytes. While murine studies have greatly increased
our understanding of BAT, it is becoming clear that human BAT does not exactly
resemble that of the mouse, highlighting the need for human in vitro models of brown
adipocytes. Several different human brown adipocyte models will be discussed here,
along with the potential to improve brown adipocyte culture through recreation of the
BAT microenvironment.
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THE OBESITY PANDEMIC
Obesity, defined as excessive fat accumulation, has reached pandemic proportions. Among adults,
more than 650 million were obese in 2016 (BMI ≥ 30), with over 340 million obese or overweight
(BMI≥ 25) children and adolescents (1). Obesity is associated with the metabolic syndrome, which
comprises a cluster of metabolic abnormalities including insulin resistance, obesity, dyslipidemia,
and hypertension, which are risk factors for cardiovascular disease and diabetes (2). Furthermore,
obesity is a risk factor for cancer and musculoskeletal disorders, including osteoarthritis, among
other diseases (3, 4). Thus, obesity places a substantial burden on society and healthcare systems
and despite extensive research into the mechanisms controlling energy balance, body weight, and
appetite, safe and effective measures to treat and prevent obesity are lacking.
BROWN ADIPOSE TISSUE
Brown adipose tissue (BAT) has become a focus area for weight loss therapies. This tissue, evolved
to help maintain core body temperature, is able to burn nutrients as heat, thereby increasing total
energy expenditure (5). This process is known as non-shivering thermogenesis and is mediated
by the mitochondrial uncoupling protein1 (UCP1), and BAT activation leads to increased energy
expenditure and decreased metabolic efficiency.
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BAT has been extensively studied in the mouse, and these
studies have revealed an important role for BAT in the control
of energy balance and whole-body metabolism. BAT activation
has, for instance, been shown to positively influence plasma
triglyceride and cholesterol levels, atherosclerosis development,
glucose tolerance, insulin sensitivity, and hepatic steatosis, in
addition to promoting weight loss (6–9).
BEIGE ADIPOSE TISSUE
Another type of adipose tissue (AT), which has received
considerable attention for the treatment of obesity, is beige AT,
which arises from white adipose tissue (WAT) browning. WAT
browning is characterized by the presence of multilocular, brown
adipocyte (BA)-marker expressing adipocytes within WAT—so-
called beige or brite adipocytes. Beige adipocytes can appear
in WAT, mainly subcutaneous (sc)WAT, after cold exposure,
hypercaloric diet, β-adrenergic stimulation, and exercise (10),
and are believed to influence metabolism similarly to BAT (11,
12). Although beige adipocytes show high expression of UCP1
(13), they are believed to originate from different lineages than
BAs (14), although this is still debated.
BAT IN HUMANS—BEIGE OR BROWN?
In humans, BAT mass and prevalence have been found to
correlate negatively with BMI, diabetes status, and glucose
plasma levels (15), and cold-induced BAT activation also had
beneficial metabolic effects and induced weight loss (16, 17),
suggesting that human and murine BAT may have similar
metabolic roles. It has been estimated that adult lean men
may have around 330ml of cold-inducible BAT, with lower
volumes (around 130ml) found in obese men (18). Furthermore,
seasonal changes in WAT thermogenic gene expression have
been described (19), suggesting that human WAT has the
capacity for browning, although the impact of browning on
whole-body metabolism is unclear.
Based on this ability of BAT to increase energy expenditure
and improve metabolic function, BAT seems a likely target for
the development of obesity therapeutics. Importantly, the efficacy
of these therapeutics depends on whether activation of BAT in
adults is able to significantly influence energy expenditure. Cold
exposure in adults is able to increase energy expenditure varying
from 20 kcal/day (20) to more than 100 kcal/day (17), and this
can be increased further through chronic cold adaptation or
increased BAT mass (17, 18).
A growing body of research is focusing on identifying genes
and molecules able to influence BAT biology; however, one
question is how well the findings in mice translate to humans.
First, there is debate around whether human BAT resembles
murine brown or beige AT more closely. Analyses of human
neck fat have revealed that on a molecular level, deep neck
fat mostly resembles that of murine canonical BAT, whereas
the superficial neck fat may be more white or beige (21). In a
study characterizing beige adipocytes, Wu et al. (13) generated
murine brown and beige adipocyte gene expression signatures.
Comparing these signatures with human supraclavicular BAT,
they found that human BAT is closer to murine beige than
brownAT. A similar study comparingmurine AT gene signatures
with human BAT from multiple anatomical locations came to
the same conclusion (22). In contrast, a recent study suggests
that when mice are physiologically humanized, meaning housed
at thermoneutrality, fed a “Western diet,” and examined at 9–
11 months old, their BAT becomes comparable with human
supraclavicular BAT (23), although this conclusion has raised
some discussion (24). This debate may likely be solved as the
composition of human and murine brown and beige AT is better
characterized with the help of more sophisticated techniques
such as single-cell RNA sequencing. Owing to discrepancies
between mRNA and protein expression levels of certain genes,
including UCP1 (25), purely transcriptomic analysis of different
BA populations may not be adequate to fully characterize their
identity and thermogenic potential. To this end, protein analysis
and functional characterization, including β-adrenergic response
and bioenergetics, are required.
Second, whereas treatment with β3-adrenergic receptor
(β3AR) agonists in mice is able to selectively stimulate BAT
and protect against diet-induced obesity, these effects are not
seen in humans at doses low enough to prevent cardiovascular
side effects (26, 27). Interestingly, a recent study found that
the β1AR may be the predominant βAR in human BAT (28),
highlighting another confounding issue when translating murine
BAT studies to human biology. Other attempts to selectively
activate thermogenesis through sympathomimetic drugs or
mitochondrial uncouplers have not been successful (26). Thus,
to achieve selective and safe activation of BAT in humans, we
may need to look beyond adrenergic stimulation or uncoupling
mechanisms and instead focus on alternative pathways to
target BAT biology. Specifically, rather than focusing exclusively
on increasing the activation of existing BAT, other strategies
could include increasing BAT mass through differentiation of
progenitors, or increasing thermogenic activity in WAT through
WAT browning.
STRATEGIES FOR THE TARGETING OF
HUMAN BAT
Increased energy expenditure in humans through BAT
thermogenesis could be achieved by (a) increasing functional
BAT mass, (b) increasing BAT activity, and (c) increasing
WAT browning.
Increased BAT Mass/Recruitment
Increased BAT mass could be achieved through the recruitment
of BA progenitors. As mentioned earlier, decreased BAT mass
is found in obese individuals—the very individuals the BAT
therapeutics are intended for—and thus even if a method to
selectively activate BAT was found, this may be of limited use to
obese recipients. However, BAT activity can be enhanced through
cold acclimation even in obese individuals (29), suggesting the
presence of BA precursors, the differentiation of which may be
promoted given appropriate stimulation. The development of
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targeted approaches to induce differentiation of BA progenitors
requires in-depth knowledge of the developmental mechanisms
of human BAT, which currently does not exist. Furthermore,
newly differentiated BAs would still require activation through
sympathetic or alternative pathways.
Increased BAT Activity
Increased BAT activity, as discussed earlier, has been challenging
to achieve without cardiovascular side effects. However, several
molecules have been identified as possible therapeutic targets
for the activation of BAT, reviewed in (30). First, members
of the bone morphogenetic protein (BMP) family have been
reported to play roles in BAT or WAT browning, mainly using
murine models. These include, among others, BMP4, which may
promote browning of WAT (31, 32), BMP7, which can promote
BAT development and activation (33) as well as white adipocyte
(WA) browning (31), and BMP8B, which was found to increase
the adrenergic response of BAT and induce scWAT browning
(34, 35). In addition, factors released from heart, muscle, liver,
and immune cells have been shown to regulate thermogenesis
(30). Although these studies reveal several candidate targets, most
of them have been conducted in murine models or in vitro, and
tangible therapeutics are still far from a reality.
Increased WAT Browning
Finally, increased WAT browning is a strategy which may
have substantial potential given the high abundance of
WAT compared with BAT. However, as for BAs, the safe
activation of beige adipocytes likely requires identification of
specific molecular pathways to induce WAT browning that
do not rely directly on adrenergic or uncoupling actions.
These include fibroblast growth factor 21 (FGF21), which
may regulate browning of scWAT through activation of
peroxisome proliferator-activated receptor gamma coactivator
1-alpha (PGC1α) (36), as well as through UCP1-independent
mechanisms (37). Another potential molecule is irisin, which
may activate UCP1 in scWAT via p38-MAPK/ERK pathways
(38), although the levels of circulating irisin and its metabolic
effects in humans are debated (39, 40). In addition, more studies
on human WAT browning are necessary to determine whether
this process is able to influence whole-body energy expenditure
in a notable manner.
The three strategies presented earlier are all limited by the
lack of knowledge regarding human thermogenic adipocyte
development and function. This lack of knowledge stems
principally from the lack of robust in vitromodels of human BAs.
IN VITRO MODELS OF HUMAN BAT
Models of human BAs have been developed by several different
groups and from starting material such as primary BAT,
fibroblasts, muscle cells, adult stem cells, and pluripotent stem
cells, among others. Some of these models are discussed later and
represented in Figure 1.
Primary Cell-Derived BA Models
The study of human primary BAT is limited by the scarceness
of the disperse tissue and the need for invasive procedures
to obtain biopsies. Nonetheless, several in vitro BA models
derived from primary human BAT do exist. If one does have
access to primary BAT, preadipocytes from non-viable human
fetal interscapular BAT can be cultured and differentiated in
vitro (41); however, these are not stable cell lines and are thus
not a viable long-term solution for the study of human BAT.
To this end, immortalized human BA lines may be of more
use. One of these is the PAZ6 cell line from immortalized
infant BAT vascular stromal cells (42). These cells readily
differentiate to BAs and respond to β-adrenergic stimulation;
however, the differentiation potential of these cells declines
with increasing passage number, significantly limiting their
experimental value. Similarly, subcloned immortalized BA-like
cell lines have been generated from adult supraclavicular AT
stromal vascular fraction (SVF) (43) and neck AT SVF (44). In
addition, a more heterogeneous BA-like cell model was created
from adult deep neck AT SVF without subcloning (45). These BA
cell models demonstrated expression of UCP1, lipolytic response
to cAMP (43), and increased oxygen consumption in response
to β-adrenergic stimulation (44, 45), and two of the lines were
maintained for at least 20 passages (44, 45). These cell lines thus
represent useful models for the study of human BAT. However,
their generation does require access to primary tissue, and they,
therefore, come from limited starting material, which means that
these cell lines will deplete eventually.
Rather than using primary BAT, BA-like cells can be directly
generated from human dermal fibroblasts, eliminating the
need for invasive biopsies. One study demonstrated that
overexpression of CCAAT/enhancer binding protein beta
(CEBPB) and avian myelocytomatosis viral oncogene homolog
(C-MYC), coupled with an adipogenic cocktail, induced
conversion of human fibroblasts to BA-like cells (46). Another
study demonstrated the direct conversion of primary fibroblasts
into BA-like cells with only chemical compounds, without using
gene transfer (47). These compounds included rosiglitazone,
which is an agonist of peroxisome proliferator-activated receptor
gamma (PPARγ), and known to promote browning (48).
Alternatively, BA-like cells were shown to be differentiated
from fetal and adult muscle progenitor cells expressing CD34,
a marker of hematopoietic progenitors as well as vascular
endothelial progenitors (49), thus supporting the common
lineage of skeletal muscle and BAT. This technique does require
invasive biopsies; however, muscle tissue may be more accessible
than BAT.
In addition to primary tissue access, a limitation of the
aforementioned models is the inherent risk of cell depletion.
Thus, to circumvent this limitation, cell lines can be generated
from human stem cells.
Generation of Adipocytes From Stem Cells
Multipotent Stem Cell–Derived BAs
Multipotent mesenchymal stem cells (MSCs) are adult stem
cells able to differentiate into a range of mesodermal cell types
including adipocytes, and can be isolated from several tissues
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FIGURE 1 | Schematic of in vitro human BA models. Human BA models have been generated from infant BAT (1), deep neck and supraclavicular BAT (2), dermal
fibroblasts (3), MSCs from AT and bone marrow (4), skeletal muscle progenitor cells (5), and hPSCs (6). Standard adipogenic cocktails or variations were used for the
differentiations unless otherwise indicated. SVF, stromal vascular fraction; BAs, brown adipocytes; MSCs, mesenchymal stem cells; h(i)PSCs, human (induced)
pluripotent stem cells; BAPs, BA progenitors; EB, embryoid body; RA, retinoic acid.
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such as bone marrow, blood, and AT (50). MSCs isolated from
human AT (termed human multipotent adipose-derived stem
(hMADS) cells) could be differentiated to BA-like cells when
stimulated with a PPARγ agonist on top of an adipogenic cocktail
(51), and with the addition of BMP7 (52). Similarly, bone
marrow–derived MSCs may also be able to differentiate to BA-
like cells when overexpressing PPARGC1A (53). Thus, MSCs are
a useful tool for the generation of BA-like cells, and the self-
renewal ability of MSCs gives unlimited starting material, at least
theoretically. As an alternative to MSCs, human pluripotent stem
cells (hPSCs) have been used for the generation of BA cell models.
Pluripotent Stem Cell–Derived BAs
hPSCs are advantageous for the generation of cell models
for several reasons, including that they are relatively easy to
genetically engineer. Because of their pluripotency and the fact
that protocols exist to differentiate hPSCs into a wide range of
cell types (54), it is possible to generate isogenic disease models
of cells from all three embryonic germ layers. Furthermore,
the use of human induced (hi)PSCs, which are reprogrammed
from human somatic cells (55), enables the generation of disease
models with patient-specific genetic backgrounds.
Some studies have demonstrated the generation of adipocytes
from hPSCs. Mature white and brown adipocytes were generated
from hPSCs through transfection with lentiviral constructs
to overexpress PPARG2 or PPARG2, CEBPB, and PRDM16,
respectively (56). In this study, hPSCs were first differentiated
into MSCs using embryoid bodies (EBs), after which transgene
expression was induced and an adipogenic cocktail was given. A
similar method was used to generate BAs from hiPSCs through
transduction of PRDM16 (46). Here, EBs were generated in the
presence of retinoic acid (RA), to obtain more myoblast-like
cells (57), accounting for the reduced transgene requirement.
Overexpression of transgenes in hPSCs is an efficient method for
the generation and study of mature cell types (58–60), although
it can be argued that this method of differentiation may not
follow natural developmental steps and may instead shunt some
of these pathways. Thus, this technique may not be optimal
for the generation of a human BA model for the study of
BA development.
Another group demonstrated the differentiation of BA
progenitors from hiPSCs through EB formation and adipogenic
cocktails (61). The differentiation efficiency was reported to be
low but could be improved through overexpression of paired box
3 (PAX3), a marker of BA progenitors (61). A similar method
was used to generate BA progenitors from hiPSCs without gene
transfer, although this study reports higher differentiation yield,
possibly due to inhibition of TGFβ signaling (62). TGFβ signaling
has been shown to induce the conversion of endothelial cells to a
moremesenchymal phenotype (63), and these findings, therefore,
suggest an important role of endothelial cells in the adipogenic
niche. The generation of BA-like cells from hPSCs using EB
formation and a hemopoietin cocktail has also been reported
(64), which may suggest that the developmental origin of BAs is
more diverse than previously believed. Finally, BA-like cells were
generated from hiPSCs in cytokine-free medium through the
formation of spheroids (65), although the molecular mechanisms
of this differentiation method remain unclear.
Although hPSCs can, in theory, give rise to any cell type of
the human body, their immature/embryonic state means that it
can be difficult to generate mature cell types from hPSCs without
forward programming. This issue does not arise when using
BA models derived from primary adult AT. As an alternative,
hPSC-derived BAs can be matured in vivo by transplantation
into mice, which is also a method of functional validation of
the generated BAs (46, 64, 65). Currently, transplantation in vivo
may be the best technique for recapitulation of the physiological
BAT microenvironment; however, advances are also being made
toward recreating BAT in vitro using 3D cell cultures.
RECAPITULATING THE BA
MICROENVIRONMENT IN VITRO
Long-term culture of adipocytes in vitro can be difficult
because of the buoyancy of mature, lipid-laden adipocytes,
which makes their attachment to 2D cell culture plates difficult
(66). Furthermore, true understanding of BAT biology requires
recapitulation of the in vivo BA microenvironment—the BA
niche. In vivo, BAT is a highly vascularized and innervated tissue,
containing not only BAs but also endothelial cells, fibroblasts,
progenitor cells, and immune cells (5, 30). Furthermore, the
extracellular matrix (ECM) of the AT is vital as a structural
scaffold and to facilitate adipocyte differentiation, AT expansion,
mechanotransduction, and biomolecule signaling (67–69).
Culturing BAs in 3D
A first step toward recapitulating BAT in vitro may be to
use 3D cultures, which can provide mechanical support, allow
physiological cell organization, and prevent loss of mature
adipocytes (70). 3D culture techniques are successful for WA
culture (71), allowing in vitro culture of unilocular primary
mature human WAs (72, 73). Unilocular WAs can also develop
in vitro when differentiated in spheroids (74–76).
Fewer 3D culture systems have been tested on BAs, potentially
because the focus is still on the generation of useful BA cell
models rather than their further development. Using hanging
drop spheroid formation followed by culture in ultra-low
attachment plates, Klingelhutz et al. (76) demonstrated improved
differentiation of murine BAT SVF compared with 2D. Alginate
microstrands have also been used for the differentiation of BAs
from murine embryonic stem cells and brown preadipocytes
(77). Using 3D printed hyaluronic acid/gelatin gels, Kuss et al.
(78) showed that whereas immortalized human WA progenitors
prefer soft gels, immortalized human BA progenitors prefer
stiffer gels, suggesting that developments within WA 3D culture
methods cannot necessarily be directly translated to BA cultures.
ECM and Vascularization
The next step toward recapitulating BAT in vitro is the addition
of ECM and supporting cell types. It is possible to generate 3D
scaffolds from ECM proteins such as collagens and glycoproteins
(71), or to incorporate ECM components into synthetic
hydrogels (72, 79). However, to recreate the human BAT ECM
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in vitro, its composition must first be fully characterized in vivo,
in both physiological and pathophysiological states.
For the generation of functional models of AT, vascularization
is an important parameter, which can also aid engraftment in
vivo during transplantation studies, as shown (74). Angiogenic
signals, including VEGF (vascular endothelial growth factor),
play important roles not only in BAT function but also
in the development of BAs (80–83). For instance, VEGFA
is able to trigger local angiogenesis in BAT, leading to
brown adipogenesis and upregulation of Ucp1 and Pgc1α (81).
Vascularized (white) adipocyte spheroids can be generated
using AT SVF, which contains endothelial cells as well as
preadipocytes, or by coculturing adipocytes with endothelial
cells (74, 75). For the generation of vascularized human
BA models, it may be advantageous to focus on coculture
methods, to avoid the need for primary tissue. Similar challenges
exist regarding the integration of immune cells into the
BA cultures.
DISCUSSION
Our understanding of BAT in mice and humans has increased
significantly over the last decade, and with this understanding, we
are moving closer to the development of therapeutics targeting
BAT for obesity treatment. One of the main limitations in the
field is the limited understanding of human BAT, including
its development and molecular signature. These questions
are steadily being tackled through in-depth characterization
of primary human BAT and the development of human in
vitro BA models. Human BA models can be generated from
immortalization of primary human BAs, from multipotent stem
cells or hPSCs, among others, and each of these methods has
distinct advantages and limitations. For instance, in vitromodels
generated from adult BAT may represent the most mature BA
models, whereas hPSC-derived BAs may be less mature unless
forward programming is employed. In contrast, hPSCs are useful
for disease modeling involving genetic engineering or patient-
specific genetic backgrounds. Without a defined molecular
signature for human BAT, lacking due to the heterogeneity
and disperse anatomical distribution of BAT depots, it may,
however, be challenging to determine which in vitromodel is the
best. Furthermore, as BAT does not exclusively consist of BAs,
true recapitulation of this tissue involves modeling of the BAT
microenvironment, including physiological BA organization in
3D, crosstalk with supporting cells such as immune cells,
vascularization, and an ECM to facilitate BA differentiation and
cell–cell signaling.
The road toward the development of obesity therapeutics
targeting human BAT thus has plenty of challenges.
However, with continued development of BA models and
characterization of the in vivo depots, these challenges may soon
be overcome.
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